Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy

Br J Haematol. 2020 Oct;191(1):126-129. doi: 10.1111/bjh.16951. Epub 2020 Jul 15.
No abstract available

Keywords: B-cell lymphoma; anti-CD19 CAR T cell; chronic HBV infection; hepatitis B reactivation; resolved HBV infection.

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Female
  • Hepatitis B / immunology*
  • Hepatitis B virus / physiology*
  • Humans
  • Immunotherapy, Adoptive*
  • Lymphoma, B-Cell* / immunology
  • Lymphoma, B-Cell* / therapy
  • Lymphoma, B-Cell* / virology
  • Male
  • Middle Aged
  • Risk Factors
  • Virus Activation / immunology*